A RAS renaissance: Emerging targeted therapies for KRAS-mutated non-small cell lung cancer

Clinical Cancer Research

Volumn 20, Issue 15, 2014, Pages 3921-3930

  Vasan, Neil ^a   Boyer, Julie L ^b   Herbst, Roy S ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; AUROTHIOMALATE; BENZIMIDAZOLE; BORTEZOMIB; CYCLIN DEPENDENT KINASE 4; CYSMETHYNIL; DOCETAXEL; ENZYME; ERLOTINIB; EVEROLIMUS; FARNESYLTRANSFERASE; GERANYLGERANYLTRANSFERASE I; METHOTREXATE; PHOSPHODIESTERASE; PHOSPHODIESTERASE DELTA; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN S ISOPRENYLCYSTEINE O METHYLTRANSFERASE; RAS CONVERTING ENZYME 1; RETASPIMYCIN; SALIRASIB; SELUMETINIB; SORAFENIB; TIPIFARNIB; TRANSCRIPTION FACTOR GATA 2; TRANSFERASE; UNCLASSIFIED DRUG; WT1 PROTEIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ANTINEOPLASTIC ACTIVITY; BCL XL GENE; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CDK4 GENE; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GATA 2 GENE; GENE; GENE MUTATION; GENE TARGETING; HUMAN; LETHALITY; LUNG NON SMALL CELL CANCER; MEMBRANE ASSOCIATION; MEMBRANE BIOLOGY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUTATION RATE; NONHUMAN; ONCOGENE K RAS; ONCOGENE RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYNTHETIC LETHALITY; TBK1 GENE; WT1 GENE; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84905459651     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1762     Document Type: Review

References (79)

1. Barbacid M. Ras genes. Annu Rev Biochem 1987;56:779-827.
2. Mitin N, Rossman KL, der CJ. Signaling interplay in Ras superfamily function. Curr Biol CB 2005;15:R563-74.
3. Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: a conserved switch for diverse cell functions. Nature 1990;348:125-32.
4. Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007;129:865-77.
5. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945-50.
6. Scheidig AJ, Burmester C, Goody RS. The pre-hydrolysis state of p21 (ras) in complex with GTP: new insights into the role of water molecules in the GTP hydrolysis reaction of ras-like proteins. Structure 1999;7:1311-24.
7. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011;11:761-74.
8. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
10. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008;9:517-31.
11. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009;6:201-5.
12. Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 1984;312:71-5.
13. der CJ, Finkel T, Cooper GM. Biological and biochemical properties of human rasH genes mutated at codon 61. Cell 1986;44:167-76.
14. Leone-Kabler S, Wessner LL, McEntee MF, D'Agostino RB Jr, Miller MS. Ki-ras mutations are an early event and correlate with tumor stage in transplacentally-induced murine lung tumors. Carcinogenesis 1997;18:1163-8.
15. Garassino MC, Marabese M, Rusconi P, Rulli E, Martelli O, Farina G, et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol 2011;22:235-7.
16. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
17. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012;104:228-39.
18. Miller MS, Miller LD. RAS mutations and oncogenesis: not all RAS mutations are created equally. Front Genet 2011;2:100.
19. Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS. Inhibition of purified p21ras farnesyl: protein transferase by Cys-AAX tetrapeptides. Cell 1990;62:81-8.
20. Ashby MN. CaaX converting enzymes. Curr Opin Lipidol 1998;9:99-102.
21. Mor A, Philips MR. Compartmentalized Ras/MAPK signaling. Annu Rev Immunol 2006;24:771-800.
22. Hancock JF, Paterson H, Marshall CJ. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 1990;63:133-9.
23. Rowinsky EK. Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors. J Clin Oncol 2006;24:2981-4.
24. Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 2006;47:15-31.
25. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, Desolms SJ, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995;1:792-7.
26. Van Cutsem E, Van De Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-8.
27. Lobell RB, Liu D, Buser CA, Davide JP, De Puy E, Hamilton K, et al. Preclinical and clinical pharmacodynamic assessment of L-778, 123, a dual inhibitor of farnesyl: protein transferase and geranylgeranyl: protein transferase type-I. Mol Cancer Ther 2002;1:747-58.
28. Gotlib J. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr Hematol Rep 2005;4:77-84.
29. Johnston S R D, Hickish T, Ellis P, Houston S, Kelland L, Dowsett M, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003;21:2492-9.
30. Blum R, Cox AD, Kloog Y. Inhibitors of chronically active ras: potential for treatment of human malignancies. Recent Patents Anticancer Drug Discov 2008;3:31-47.
31. Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben-Baruch G, Marciano D, et al. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 1999;18:2579-88.
32. Riely GJ, Johnson ML, Medina C, Rizvi NA, Miller VA, Kris MG, et al. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. J Thorac Oncol 2011;6:1435-7.
33. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997;272:14459-64.
34. Tsimberidou AM, Chandhasin C, Kurzrock R. Farnesyltransferase inhibitors: where are we now? Expert Opin Investig Drugs 2010;19:1569-80.
35. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 2010;70:7580-90.
36. Sebti SM, der CJ. Opinion: Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 2003;3:945-51.
37. https://clinicaltrials.gov/ct2/results?term=farnesyltransferase [Internet]. [cited 2014 Jun. 16]. Available from: http://www.clinicaltrials.gov/ .
38. Bergo MO, Ambroziak P, Gregory C, George A, Otto JC, Kim E, et al. Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol 2002;22:171-81.
39. Wahlstrom AM, Cutts BA, Karlsson C, Andersson K M E, Liu M, Sjogren A-KM, et al. Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease. Blood 2007;109:763-8.
40. Manandhar SP, Hildebrandt ER, Schmidt WK. Small-molecule inhibitors of the Rce1p CaaX protease. J Biomol Screen 2007;12:983-93.
41. Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ, et al. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest 2004;113:539-50.
42. Wahlstrom AM, Cutts BA, Liu M, Lindskog A, Karlsson C, Sjogren A-KM, et al. Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. Blood 2008;112:1357-65.
43. Winter-Vann AM, Baron RA, Wong W, Dela Cruz J, York JD, Gooden DM, et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci U S A 2005;102:4336-41.
44. Winter-Vann AM, Kamen BA, Bergo MO, Young SG, Melnyk S, James SJ, et al. Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sci U S A 2003;100:6529-34.
45. Chandra A, Grecco HE, Pisupati V, Perera D, Cassidy L, Skoulidis F, et al. The GDI-like solubilizing factor PDEd sustains the spatial organization and signalling of Ras family proteins. Nat Cell Biol 2012;14:148-58.
46. Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A, Hoffmann M, et al. Small molecule inhibition of the KRAS-PDEd interaction impairs oncogenic KRAS signalling. Nature 2013;497:638-42.
47. Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting Ras proteins. Genes Cancer 2011;2:359-72.
48. Palmioli A, Sacco E, Abraham S, Thomas CJ, Di Domizio A, De Gioia L, et al. First experimental identification of Ras-inhibitor binding interface using a water-soluble Ras ligand. Bioorg Med Chem Lett 2009;19:4217-22.
49. Rosnizeck IC, Graf T, Spoerner M, Träankle J, Filchtinski D, Herrmann C, et al. Stabilizing a weak binding state for effectors in the human ras protein by cyclin complexes. Angew Chem Int Ed Engl 2010;49:3830-3.
50. Patgiri A, Yadav KK, Arora PS, Bar-Sagi D. An orthosteric inhibitor of the Ras-Sos interaction. Nat Chem Biol 2011;7:585-7.
51. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A 2012;109:5299-304.
52. Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, et al. Discovery of small molecules that bind to K-Ras and inhibit Sosmediated activation. Angew Chem Int Ed Engl 2012;51:6140-3.
53. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 2013;503:548-51.
54. Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A. Searching for synthetic lethality in cancer. Curr Opin Genet Dev 2011;21:34-41.
55. Patel PH, Chadalavada R S V, Chaganti R S K, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006;12:7215-20.
56. Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A 2011;108:8773-8.
57. Guo W, Wu S, Wang L, Wei X, Liu X, Wang J, et al. Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition. PLoS ONE 2011;6.
58. Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C, et al. Phase I dose escalation study of the protein kinase C iota inhibitor aurothiomalate for advanced non-small cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs 2013;24:1079-83.
59. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-48.
60. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12.
61. Chien Y, Kim S, Bumeister R, Loo Y-M, Kwon SW, Johnson CL, et al. RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 2006;127:157-70.
62. Ou Y-H, Torres M, Ram R, Formstecher E, Roland C, Cheng T, et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 2011;41:458-70.
63. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet 2005;37:48-55.
64. Vicent S, Chen R, Sayles LC, Lin C, Walker RG, Gillespie AK, et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest 2010;120:3940-52.
65. Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S-I, et al. Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer J Int Cancer 2002;100:297-303.
66. Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010;18:63-73.
67. Kumar MS, Hancock DC, Molina-Arcas M, Steckel M, East P, Diefenbacher M, et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 2012;149:642-55.
68. Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne PH, Kuznetsov H, et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res 2012;22:1227-45.
69. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013;23:121-8.
70. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
71. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
72. Mok T S K, Paz-Ares L, Wu Y-L, Novello S, Juhasz E, Aren O, et al. Association between tumor EGFR and KRas mutation status and clinical outcomes in NSCLC patients randomized to sorafenib plus best supportive care (BSC) or BSC alone: subanalysis of the Phase III MISSION Trial. Ann Oncol 2012;23: ixe1-ixe30.
73. BATTLE-2 program: a biomarker-integrated targeted therapy study - ClinicalTrials.gov [Internet]. [cited 2014 Jun. 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01248247.
74. Jäanne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. Selumetinib plus docetaxel for KRAS-mutant advanced nonsmall-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013;14:38-47.
75. Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2010;5:1630-6.
76. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012;483:613-7.
77. Bortezomib in KRAS-mutant non-small cell lung cancer in never smokers or those with KRAS G12D - ClinicalTrials.gov [Internet]. [cited 2014 Jun. 16]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01833143.
78. Phase 1b/2 study of retaspimycin HCl (IPI-504) in combination with everolimus in KRAS mutant non-small cell lung cancer - ClinicalTrials. gov [Internet]. [cited 2014 Jun. 16]. Available from: http://www.clinicaltrials.gov/ ct2/show/NCT01427946.
79. Randomized phase II study of AZD6244 (MEK inhibitor) with erlotinib in KRAS wild type advanced NSCLC and a randomized phase II study of AZD6244 with erlotinib in mutant KRAS advanced NSCLC - Clinical-Trials.gov [Internet]. [cited 2014 Jun. 16]. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT01229150.